Results 21 to 30 of about 8,661 (182)

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Frontiers in Pharmacology, 2023
Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 (COVID-19). However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited.
Jiayi Yan, Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou, Shan Mou   +11 more
doaj   +1 more source

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19

Frontiers in Pharmacology, 2023
Background: Hemodialysis patients have a high risk of severe/critical COVID-19 and related high mortality, but nirmatrelvir/ritonavir is not recommended for hemodialysis patients with COVID-19 infection because of lack of evidence of safety.Objectives ...
Jiayue Lu, Hong Cai, Yujun Hao, Zhang Lin, Shang Liu, Yaping Zhan, Li Ding, Meilan Huang, Zhenyuan Li, Lan Xu, Xiujuan Yan, Li Yang, He Zhang, Wei Zhang, Li Zhao, Junli Zhao, Ting Wang, Leyi Gu   +17 more
doaj   +1 more source

Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong [PDF]

, 2023
Importance: Diabetes and COVID-19 are both global pandemics, and type 2 diabetes is a common comorbidity in patients with acute COVID-19 and is proven to be a key determinant of COVID-19 prognosis.
Au, Ivan CH, Chung, Matthew SH, Cowling, Benjamin J, Lau, Eric HY, Lau, Kristy TK, Lee, Chi Ho, Lui, David TW, Wong, Carlos KH, Woo, Yu Cho   +8 more
core   +1 more source

Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study

Scientific Reports, 2023
We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who ...
Seth Congdon, Zev Narrowe, Nang Yone, Jacob Gunn, Yuting Deng, Priya Nori, Kelsie Cowman, Marjan Islam, Sharon Rikin, Joanna Starrels   +9 more
doaj   +1 more source

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir. [PDF]

, 2023
The SARS-CoV-2 main protease (3CLpro) has an indispensable role in the viral life cycle and is a therapeutic target for the treatment of COVID-19. The potential of 3CLpro-inhibitors to select for drug-resistant variants needs to be established. Therefore,
Bardiot, Dorothée, Beigelman, Leonid, Blatt, Lawrence M, Boland, Sandro, Chaltin, Patrick, De Jonghe, Steven, De Vita, Chloe, Deval, Jerome, Donckers, Kim, Ebert, Nadine, Jekle, Andreas, Jochmans, Dirk, Liu, Cheng, Maes, Piet, Marchand, Arnaud, Neyts, Johan, Raboisson, Pierre, Stevens, Sarah K, Stoycheva, Antitsa, Symons, Julian A, Thiel, Volker, Trüeb, Bettina, Vandyck, Koen, Vangeel, Laura, Vanmechelen, Bert   +24 more
core   +2 more sources

Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report

Viruses, 2023
Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and to report a case of Coronavirus Disease 2019 (COVID-19) cured with this ...
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, Sabrina Bastianelli, Sara Pierucci, Chiara Busti, Lavinia Maria Saraca, Luca Capogrossi, Maria Bruna Pasticci, Daniela Francisci   +9 more
doaj   +1 more source

Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection [PDF]

, 2023
Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID-19-associated morbidity. In particular, patients with impaired humoral immunity have shown a high risk of persistent infection.
Bartoletti M., Beccacece A., Bussini L., Cantiani A., Casadei B., Chionsini M. C., D'Abramo A., Dentale N., Giannella M., Lazzarotto T., Nicastri E., Pasquini Z., Pellegrini C., Toschi A., Viale P., Vita S., Zinzani P.   +16 more
core   +1 more source

Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study

International Journal of Infectious Diseases, 2023
Objective: To determine if nirmatrelvir-ritonavir 300mg/100mg treatment for 5 days in high-risk outpatients with mild to moderate COVID-19 symptoms was associated with a reduction in hospitalization, intensive care unit (ICU) admission, and death ...
Ee Vien Low, Mohan Dass Pathmanathan, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +12 more
doaj   +1 more source

Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment. [PDF]

, 2023
The SARS-CoV-2 main protease (3CLpro) is one of the promising therapeutic targets for the treatment of COVID-19. Nirmatrelvir is the first 3CLpro inhibitor authorized for treatment of COVID-19 patients at high risk of hospitalization.
Abdelnabi, Rana, Donckers, Kim, Ebert, Nadine, Jochmans, Dirk, Neyts, Johan, Thiel, Volker, Trüeb, Bettina, Weynand, Birgit   +7 more
core   +2 more sources

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study [PDF]

, 2023
Background Comparative data on mortality in COVID-19 patients treated with molnupiravir or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause mortality in community-dwelling COVID-19 patients treated with these drugs ...
Erne, Elke Maria, Russo, Pierluigi, Tacconelli, Evelina, Tascini, Carlo, Torti, Carlo   +4 more
core   +1 more source